"The increasing amount and availability of collected data (cancer imaging) and the development of novel technological tools based on Artificial Intelligence (AI) and Machine Learning (ML), provide unprecedented opportunities for better cancer detection and classification, image optimization, radiation reduction, and clinical workflow enhancement. The INCISIVE project aims to address three major open challenges in order to explore the full potential of AI solutions in cancer imaging: (1) AI challenges unique to medical imaging, (2) Image labeling and annotation and (3) Data availability and sharing. In order to do that INCISIVE plans to develop and validate: (1) an AI-based toolbox that enhances the accuracy, specificity, sensitivity, interpretability and cost-effectiveness of existing cancer imaging methods, (2) an automated-ML based annotation mechanism to rapidly produce training data for machine learning research and (3) a pan-European repository federated repository of medical images, that will enable the secure donation and sharing of data in compliance with ethical, legal and privacy demands, increasing accessibility to
datasets and enabling experimentation of AI-based solutions. The INCISIVE models and analytics will utilize various cancer imaging scans, biological data and EHRs, and will be trained with 1 PB of available data provided by 8 partners within the project. INCISIVE solution will be investigated in four validation studies for Breast, Prostate, Colorectal and Lung Cancer, taking place in 8 pilot sites, from 5 countries (Cyprus, Greece, Italy, Serbia and Spain), with participation of at least 2,600 patients and a total duration of 1.5 year. INCISIVE moves beyond the state of the art, by improving sensitivity and specificity of lower cost scanning methods, accurately predicting the tumor spread, evolution and relapse, enhancing interpretability of results and “democratizing” imaging data".
https://incisive-project.eu/

Contact person:  Prof. dr Tatjana Lončar-Turukalo
Period of realization: 2020 – 2024
ID: H2020-SC1-FA-DTS-2019